ClinicalTrials.gg
Status unknownNCT04923607Updated Jun 11, 2021

Phase I Clinical Trial of TQC2731 Injection

A Phase 1 interventional study of TQC2731 and Placebo in Asthma Severe Persistent Controlled, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
121st of 182
96 · median 203
Started
2021
with 19 others
Phase 1
31 of 251
3 open now
Registered
102nd of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 121st largest by planned enrollment of the 182 interventional ones that give a count, is one of 20 that started in 2021, is one of 31 in phase 1, and was the 102nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.

03

Conditions studied

  • Asthma Severe Persistent Controlled

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects:Sign the form before the trial, fully understand the trial purpose, process and possible adverse reactions.
  • Healthy subjects:Aged between 18 and 60 years old, both men and women;
  • Healthy subjects:Female ≥45kg, male ≥50kg, (BMI) is 18-28 kg/m\^2 (including the critical value), BMI=weight (kg)/height\^2 (m\^2);
  • Asthma subjects:Aged between 18 and 70 years old, both men and women;
  • Asthma subjects:Female ≥45kg, male ≥50kg;
  • Asthma subjects:according to the GINA guidelines (GINA 2020), subjects who received middle, or high-dose ICS in asthma control drugs prescribed by the doctor at least 6 months prior to Visit 1;

Exclusion criteria

Exclusion Criteria:

  • Healthy subjects: Pregnant and lactating women;
  • Healthy subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver, gastrointestinal, skin, infection, blood, nerve, mental diseases or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial;
  • Healthy subjects:Those whose vital signs, physical examination, laboratory examination, 12-lead , and chest radiograph during the screening period are abnormal and have clinical significance;
  • Healthy subjects: virus surface antigen (HBsAg), virus antibody (Anti-HCV), antibody (Anti-HIV) and Treponema pallidum antibody (Anti-TP), any of the above positive subjects;
  • Healthy subjects:A history of infections before and during screening, including upper respiratory tract infection (URTI) and lower respiratory tract infection (LRTI), and requires antibiotic or antiviral treatment;
  • Healthy subjects:Those who have undergone surgery within 4 weeks before screening, or plan to undergo surgery during the study period;
  • Asthma subjects: Pregnant and lactating women;
  • Asthma subjects:Patients with abnormal vital signs, physical examination, 12-lead electrocardiogram results and clinical significance during the screening period;
  • Asthma subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver, gastrointestinal, skin, infection, blood, nerve, or mental illness, etc., or related chronic or acute diseases, the investigator's assessment should not participate in the trial; (except for the target disease)
  • Asthma subjects:Accompanied by clinically major lung diseases other than asthma (for example, active lung infection, non-asthmatic (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related Hypoventilation syndrome, lung cancer, α1 antitrypsin deficiency, and primary ciliary dyskinesia) or accompanied by pulmonary or systemic diseases other than asthma that lead to increased peripheral blood eosinophil counts (for example, allergic Bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, eosinophilia syndrome). COPD with mainly asthma can be included;
  • Asthma subjects:Any disease that has not been stabilized by the investigator, including but not limited to unstable cardiovascular, gastrointestinal, liver, kidney, nervous system, musculoskeletal, infectious, endocrine, metabolic, hematology, mental illness or major physical injury , May: affect the safety of the subject during the entire study period, affect the research results or interpretation of the results, and hinder the subject's ability to complete the entire study period.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    TQC2731 injection(sc.) in healthy subjects

    For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once. For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 .

    Drug: TQC2731

  • Placebo comparator
    Matching Placebo(sc.) in healthy subjects

    For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once. For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg).

    Drug: Placebo

  • Experimental
    TQC2731 injection(SAD,iv.)

    Healthy subjects received 210mg TQC2731 intravenously (iv.) once.

    Drug: TQC2731

  • Placebo comparator
    Matching Placebo(SAD,iv.)

    Healthy subjects received 210mg matching placebo intravenously (iv.) once.

    Drug: Placebo

  • Experimental
    TQC2731 injection(sc.) in asthma subjects

    For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .

    Drug: TQC2731

  • Placebo comparator
    Matching Placebo(sc.) in asthma subjects

    For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .

    Drug: Placebo

Interventions

  • TQC2731 injection

  • DrugPlacebo

    Matching placebo with no active ingredients

06

What researchers measure

Primary outcomes

  1. (healthy subject)Number of participants with abnormal clinical symptoms

    Time frame: appropriatly up to Day 253

  2. (healthy subject)Number of participants with abnormal physical examination

    Time frame: appropriatly up to Day 253

  3. (healthy subject)Number of participants with abnormal vital signs

    Time frame: appropriatly up to Day 253

  4. (asthma subject)Number of participants with abnormal laboratory examinations

    Time frame: appropriatly up to Day 253

Secondary outcomes

  1. Area under the drug-time curve

    Time frame: up to Day 253

  2. Maximum Concentration

    Time frame: up to Day 253

  3. Time to maximum concentration following drug administration

    Time frame: up to Day 253

  4. Apparent terminal elimination half-life following drug administration

    Time frame: up to Day 253

  5. Apparent volume of distribution

    Time frame: up to Day 253

  6. Clearance rate

    Time frame: up to Day 253

  7. Incidence and titer of anti-drug antibody (ADA)

    Time frame: up to Day 253

  8. Changes in forced expiratory volume (FEV1) in the first second before bronchodilator (before BD administration) from baseline

    Time frame: up to Day 253

  9. Changes in exhaled nitric oxide FENO (ppb) in the first second before bronchodilator (before BD administration) from baseline

    Time frame: up to Day 253

  10. exhaled nitric oxide FENO (ppb), peripheral blood eosinophils, and total serum IgE

    Time frame: up to Day 253

  11. Annualized incidence of acute asthma attack (AAER) and degree

    Time frame: up to Day 253

07

Study locations

1 site
  • First Affiliated Hospital of Zhengzhou University
    Henan, Zhengzhou 450052, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2021; primary completion for Aug 2023, 26 months later.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 26 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2021
First posted
Jun 11, 2021
StartEst.
Jun 25, 2021
Primary completionEst.
Aug 25, 2023
CompletionEst.
Aug 25, 2023
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04923607
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jun 25, 2021 (estimated)
Primary completion
Aug 25, 2023 (estimated)
Completion
Aug 25, 2023 (estimated)
Last update
Jun 11, 2021

Study contacts

Xiaojian Zhang, Bachelor
Contact
Zhxj0524@sina.com
+86-0371-66295651

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2731

Start the discussion